SUVN-502
Pure 5-HT$_6$ Antagonist
Well Differentiated from Competitor Clinical Candidates

First-in-Class Triple Combination - A Promising New Approach for Symptomatic Treatment of Alzheimer's Disease

Phase 2 POC Study in USA (Ongoing)
SUVN-502: Well Differentiated Asset with First-in-Class Potential

- Pure 5-HT\textsubscript{6} receptor antagonist (>1200 fold selectivity over 5-HT\textsubscript{2A} receptor)
- Superior profile that differentiates from competitor 5-HT\textsubscript{6} antagonists
- Robust efficacy in all phases of cognition (preclinical animal models)
- Potentiates the preclinical efficacy of current SOC for AD treatment
- Centrally located receptor, unlikely to potentiate AChEi mediated peripheral side effects
- No gastrointestinal side effects in aged population (Phase 1 study)
- No liver toxicity in healthy elderly subjects (Phase 1 MA study)
- No drug-drug interactions and dose limiting toxicity
- No effect of food, gender and age on pharmacokinetics
- Excellent human pharmacokinetics for once a day treatment
- Excellent margin of safety in all long term preclinical studies
- Well protected intellectual property in all major markets
SUVPN-502: Key Pharmacology Results

Efficacy Pharmacology

Brain Activity

Neurochemistry

First-in-Class Triple Combination
SUVPN-502 + Donepezil + Memantine
Superior to
Donepezil + Memantine
SUVN-502: Phase 2 POC Study in USA (Ongoing)

CT Identifier: NCT02580305

Study Arms:
- 50 mg SUVN-502 + Donepezil + Memantine,
- 100 mg SUVN-502 + Donepezil + Memantine,
- Placebo + Donepezil + Memantine

Total Number of Subjects: 537 (179 subjects per arm)

Study Population: Male and Female subjects, 50 to 85 years of age, with Moderate AD

Duration of Treatment: 26 weeks

Primary Outcome: ADAS-cog 11

Secondary Outcome: MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, C-SSRS, Safety and Tolerability
Contacts:

Venkat Jasti  
Chairman & CEO  
E-mail: info@suven.com

Ramakrishna Nirogi  
Vice President, Discovery Research  
E-mail: nvsrk@suven.com